Eckert & Ziegler hired to produce radiotherapeutic cancer drug

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Eckert & Ziegler has been commissioned by Cambridge, Mass.-based Molecular Insight Pharmaceuticals to produce a radiotherapeutic cancer medication.

The compound, Onalta, is a new radiotherapeutic product candidate under development for the treatment of certain neuroendocrine tumors, according to the company. The delivery peptide will be combined with a therapeutic radioisotope (90Y edotreotide) at Eckert & Ziegler’s plant in Braunschweig, Germany.